Quick Look Market Closing Price:
At the close: Dow +0.57% to 12800. S&P +0.69% to 1363. Nasdaq +0.29% to 2905.
Treasurys: 30-year -0.49%. 10-yr -0.16%. 5-yr -0.09%.
Commodities: Crude +0.57% to $89.31. Gold -0.63% to $1581.55.
Currencies: Euro +0.13% vs. dollar. Yen +0.30%. Pound -0.07%.
After Hours News:
VMware's preliminary Q2 results provide a moderate AH lift to some other volatile enterprise tech names. CTXS +1.7%. FFIV +1.4%. RVBD +1.4%. RHT +1.6%. CRM +3.1%. APKT +2.1%.
Yahoo (YHOO): Q2 EPS of $0.27 beats by $0.04. Revenue of $1.08B (flat Y/Y) misses by $20M. $456M worth of shares repurchased. No guidance provided. Shares +0.6% AH
Rovi (ROVI) -27.5% AH after warning it expects Q2 revenue of $158M and EPS of $0.35-$0.38, well below a consensus of $182.6M and $0.57. The company also now expects 2012 revenue and EPS guidance to $650M-$680M and $1.60-$1.90, below a consensus of $765.2M and $2.51. Rovi blames delays in securing patent licenses and launching new products, as well as weakness in electronics and ad spending. It thinks pending litigation will need to be settled before some companies agree to licenses
The FDA has approved Vivus's (VVUS) weight-loss drug Qnexa/Qsymia, marking the second approval of a new weight loss drug in less than a month. The drug, which require a doctor's prescription, won't be available until later this year. Shares were halted just prior to the FDA announcement, -7.8% before the halt
Stanley Furniture (STLY): Q2 EPS of $2.54 may not be comparable to consensus of by -$0.08. Revenue of $24.4M (-10.9% Y/Y) misses by $2.3M. Shares -2.2% AH
Intel (INTC): Q2 EPS of $0.54 beats by $0.02. Revenue of $13.5B (+4% Y/Y) misses by $60M. Expects Q3 revenue of $13.8B-$14.8B vs. $14.6B consensus. Expects 3%-5% 2012 revenue growth vs. 4.7% consensus. Shares -2% AH.
For the latest updates on the stock market, visit,